Aldeyra Therapeutics
Aldeyra Therapeutics Logo
About Aldeyra Therapeutics
Aldeyra Therapeutics Inc is a biotechnology company focused on developing and commercializing medicines for immune-mediated diseases, with an emphasis on ocular and systemic inflammatory conditions. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator in Phase III clinical trials for dry eye disease. Aldeyra is also advancing other candidates, including ADX-629 for systemic immune-mediated diseases and ADX-2191 for rare retinal diseases. The company aims to address unmet medical needs through novel mechanisms of action and ongoing clinical research.
Address
131 Hartwell Avenue, Suite 320
Lexington, 02421
United States
Year founded
2004
Number of employees
0-100
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
